JPWO2020181062A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020181062A5 JPWO2020181062A5 JP2021543386A JP2021543386A JPWO2020181062A5 JP WO2020181062 A5 JPWO2020181062 A5 JP WO2020181062A5 JP 2021543386 A JP2021543386 A JP 2021543386A JP 2021543386 A JP2021543386 A JP 2021543386A JP WO2020181062 A5 JPWO2020181062 A5 JP WO2020181062A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- amino acid
- mhc class
- acid sequence
- sequence identity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962814721P | 2019-03-06 | 2019-03-06 | |
| US62/814,721 | 2019-03-06 | ||
| PCT/US2020/021138 WO2020181062A1 (en) | 2019-03-06 | 2020-03-05 | T-cell modulatory multimeric polypeptides and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022522405A JP2022522405A (ja) | 2022-04-19 |
| JPWO2020181062A5 true JPWO2020181062A5 (enExample) | 2023-03-09 |
Family
ID=72338760
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021543386A Pending JP2022522405A (ja) | 2019-03-06 | 2020-03-05 | Ｔ細胞調節多量体ポリペプチド及びその使用方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US20220105162A1 (enExample) |
| EP (1) | EP3935080A4 (enExample) |
| JP (1) | JP2022522405A (enExample) |
| WO (1) | WO2020181062A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3558339T (pt) | 2016-12-22 | 2024-03-15 | Cue Biopharma Inc | Polipeptídeos multiméricos moduladores de células t e métodos de utilização dos mesmos |
| CA3054955A1 (en) | 2017-03-15 | 2018-09-20 | Cue Biopharma, Inc. | Methods for modulating an immune response |
| HUE069314T2 (hu) | 2017-04-28 | 2025-03-28 | Nat Jewish Health | Módszer a rheumatoid arthritis kezelésére a HLA gén RNS-vezérelt genomszerkesztésének felhasználásával |
| CA3074839A1 (en) | 2017-09-07 | 2019-03-14 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptide with conjugation sites and methods of use thereof |
| WO2021231376A2 (en) | 2020-05-12 | 2021-11-18 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| CA3212765A1 (en) * | 2021-04-21 | 2022-10-27 | Cue Biopharma, Inc. | Mhc class ii t-cell modulatory polypeptides and methods of use thereof |
| AU2022261908A1 (en) * | 2021-04-21 | 2023-10-05 | Cue Biopharma, Inc. | Mhc class ii t-cell modulatory polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof |
| CN117751136A (zh) * | 2021-05-10 | 2024-03-22 | 科罗拉多州立大学董事会法人团体 | 用于治疗自身免疫的工程化hla等位基因 |
| AU2022317127B2 (en) * | 2021-07-29 | 2025-02-27 | Nantcell, Inc. | Modified t cell receptors for the prevention and treatment of viral infections and cancer |
| WO2025111562A1 (en) * | 2023-11-22 | 2025-05-30 | Cue Biopharma, Inc. | Mhc class ii protein complexes |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| CA2115742A1 (en) | 1991-08-20 | 1993-03-04 | Ronald G. Crystal | Adenovirus mediated transfer of genes to the gastrointestinal tract |
| US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
| FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
| JPH08503855A (ja) | 1992-12-03 | 1996-04-30 | ジェンザイム・コーポレイション | 嚢胞性線維症に対する遺伝子治療 |
| AU687829B2 (en) | 1993-06-24 | 1998-03-05 | Advec, Inc. | Adenovirus vectors for gene therapy |
| JP3875990B2 (ja) | 1993-10-25 | 2007-01-31 | カンジ，インコーポレイテッド | 組換えアデノウイルスベクターおよび使用方法 |
| CA2196085C (en) * | 1994-07-29 | 2002-12-10 | Hing C. Wong | Mhc complexes and uses thereof |
| US7078387B1 (en) | 1998-12-28 | 2006-07-18 | Arch Development Corp. | Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors |
| US6287860B1 (en) | 2000-01-20 | 2001-09-11 | Isis Pharmaceuticals, Inc. | Antisense inhibition of MEKK2 expression |
| EP1578917A4 (en) | 2001-07-19 | 2008-01-23 | Perlan Therapeutics Inc | MULTIMEDIA PROTEINS AND METHODS FOR THE PRODUCTION AND USE THEREOF |
| US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
| EP1996220B2 (en) | 2006-03-06 | 2023-08-16 | Amunix Operating Inc. | Unstructured recombinant polymers and uses thereof |
| BRPI0815416A2 (pt) | 2007-08-15 | 2014-10-21 | Amunix Inc | Composições e métodos para modificar propriedades de polipeptídeos biologicamente ativos |
| EA020843B1 (ru) | 2009-02-03 | 2015-02-27 | Амуникс Оперейтинг Инк. | Удлиненные рекомбинантные полипептиды и содержащие их композиции |
| US9695410B2 (en) * | 2010-07-15 | 2017-07-04 | Technion Research & Development Foundation Limited | Isolated high affinity entities with T-cell receptor like specificity towards native complexes of MHC class II and glutamic acid decarboxylase (GAD) autoantigenic peptides |
| US20170058015A1 (en) * | 2014-06-18 | 2017-03-02 | Albert Einstein College Of Medicine, Inc. | Syntac polypeptides and uses thereof |
| WO2016198932A2 (en) * | 2015-05-06 | 2016-12-15 | Uti Limited Partnership | Nanoparticle compositions for sustained therapy |
| CN109689096A (zh) * | 2016-05-18 | 2019-04-26 | 阿尔伯特爱因斯坦医学院公司 | 变体pd-l1多肽、t细胞调节性多聚体多肽及其使用方法 |
| JP2020500015A (ja) * | 2016-11-09 | 2020-01-09 | ユーティーアイ リミテッド パートナーシップ | 組換えｐＭＨＣクラスＩＩ分子 |
| PT3558339T (pt) * | 2016-12-22 | 2024-03-15 | Cue Biopharma Inc | Polipeptídeos multiméricos moduladores de células t e métodos de utilização dos mesmos |
| CA3054955A1 (en) * | 2017-03-15 | 2018-09-20 | Cue Biopharma, Inc. | Methods for modulating an immune response |
-
2020
- 2020-03-05 EP EP20765925.1A patent/EP3935080A4/en active Pending
- 2020-03-05 WO PCT/US2020/021138 patent/WO2020181062A1/en not_active Ceased
- 2020-03-05 JP JP2021543386A patent/JP2022522405A/ja active Pending
-
2021
- 2021-08-05 US US17/394,972 patent/US20220105162A1/en not_active Abandoned
-
2025
- 2025-02-14 US US19/054,201 patent/US20250242005A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021500855A5 (enExample) | ||
| Todd et al. | A molecular basis for genetic susceptibility to insulin-dependent diabetes mellitus | |
| Spies et al. | Presentation of viral antigen by MHC class I molecules is dependent on a putative peptide transporter heterodimer | |
| McMichael et al. | Effect of mutations and variations of HLA-A2 on recognition of a virus peptide epitope by cytotoxic T lymphocytes. | |
| Todd et al. | A molecular basis for MHC class II—associated autoimmunity | |
| Terhorst et al. | Further structural studies of the heavy chain of HLA antigens and its similarity to immunoglobulins. | |
| Robb et al. | Sequence of the COOH-terminal hydrophilic region of histocompatibility antigens HLA-A2 and HLA-B7 | |
| JP2019522466A5 (enExample) | ||
| Rosloniec et al. | Identification of MHC class II and TCR binding residues in the type II collagen immunodominant determinant mediating collagen-induced arthritis | |
| JP2019512222A5 (enExample) | ||
| JPWO2020181062A5 (enExample) | ||
| Parham et al. | HLA-A, B, C: patterns of polymorphism in peptide-binding proteins | |
| Campbell et al. | MHC genes in autoimmunity | |
| Bach et al. | High affinity presentation of an autoantigenic peptide in type I diabetes by an HLA class II protein encoded in a haplotype protecting from disease | |
| JPWO2020180501A5 (enExample) | ||
| EP0286447B1 (en) | Method and agents relating to prophylactic treatment of autoimmune diseases | |
| Cook et al. | Structural Studies on the Murine Ia Alloantigens: IV. NH2-Terminal Sequence Analysis of Allelic Products of the IA and IE/C Subregions | |
| JPWO2020132297A5 (enExample) | ||
| WO1995011702A1 (en) | Prokaryotic expression of mhc proteins | |
| Toubert et al. | Epitope mapping of HLA-B27 and HLA-B7 antigens by using intradomain recombinants. | |
| Routsias et al. | Polymorphic structural features of modelled HLA-DQ molecules segregate according to susceptibility or resistance to IDDM | |
| Hogan et al. | Localization and characterization of serologic epitopes on HLA-A2 | |
| Moustakas et al. | Molecular properties of HLA‐DQ alleles conferring susceptibility to or protection from insulin‐dependent diabetes mellitus: Keys to the fate of islet β‐cells | |
| JPH10507908A (ja) | 自己免疫病の治療に役立つ化合物を同定する方法 | |
| Kaul et al. | The role of major histocompatibility complex genes in myasthenia gravis and experimental autoimmune myasthenia gravis pathogenesis |